AnaptysBio, Inc. $ANAB Shares Sold by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd lessened its stake in AnaptysBio, Inc. (NASDAQ:ANAB) by 31.4% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 22,701 shares of the biotechnology company’s stock after selling 10,400 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in AnaptysBio were worth $1,259,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of AnaptysBio by 4.5% during the fourth quarter. Vanguard Group Inc. now owns 1,544,037 shares of the biotechnology company’s stock valued at $74,855,000 after acquiring an additional 67,048 shares during the period. State Street Corp lifted its position in AnaptysBio by 20.6% in the fourth quarter. State Street Corp now owns 1,053,474 shares of the biotechnology company’s stock worth $51,072,000 after purchasing an additional 180,042 shares during the period. 683 Capital Management LLC boosted its stake in AnaptysBio by 18.5% during the 4th quarter. 683 Capital Management LLC now owns 648,093 shares of the biotechnology company’s stock valued at $31,420,000 after purchasing an additional 101,093 shares in the last quarter. Affinity Asset Advisors LLC bought a new position in AnaptysBio during the 4th quarter valued at $21,559,000. Finally, Goldman Sachs Group Inc. increased its position in shares of AnaptysBio by 20.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 398,914 shares of the biotechnology company’s stock valued at $19,339,000 after purchasing an additional 69,094 shares during the period.

AnaptysBio Trading Down 0.3%

Shares of NASDAQ ANAB traded down $0.20 during mid-day trading on Friday, reaching $66.39. The company had a trading volume of 400,964 shares, compared to its average volume of 628,133. The company has a 50-day moving average price of $60.27 and a two-hundred day moving average price of $56.95. The stock has a market cap of $1.97 billion, a PE ratio of -61.47 and a beta of 0.68. AnaptysBio, Inc. has a 1-year low of $11.40 and a 1-year high of $72.36.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Tuesday, May 12th. The biotechnology company reported ($1.84) EPS for the quarter, missing the consensus estimate of ($0.64) by ($1.20). The firm had revenue of $25.56 million during the quarter, compared to analyst estimates of $18.86 million. On average, research analysts expect that AnaptysBio, Inc. will post -1.35 EPS for the current year.

AnaptysBio declared that its board has authorized a stock repurchase program on Friday, March 27th that permits the company to repurchase $100,000.00 billion in outstanding shares. This repurchase authorization permits the biotechnology company to purchase up to 5,352,316.2% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board of directors believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Weiss Ratings lowered AnaptysBio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 13th. HC Wainwright assumed coverage on shares of AnaptysBio in a research report on Wednesday, June 10th. They issued a “buy” rating and a $95.00 price target on the stock. Piper Sandler cut their price target on shares of AnaptysBio from $95.00 to $93.00 and set an “overweight” rating for the company in a report on Monday, May 4th. Zacks Research lowered shares of AnaptysBio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 2nd. Finally, Leerink Partners set a $90.00 target price on shares of AnaptysBio in a report on Friday, May 15th. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $81.82.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.